Digital health company mySugr based in Vienna and San Diego has announced new findings that were collectedHealth in their large-scale study that took a closer look how their high-risk users use their blood glucose monitoring app.
The study was performed in cooperation with clinical trial company ProSciento, and it included over 440 mySugr participants which were selected randomly from the group of very high risk and high-engagement users. One of the core requirements for being picked was that their HbA1C had to be over 8 percent at baseline. After six months of use, results of the study showed that participants experienced on average almost a 20 percent drop in their mean glucose levels and 1.3 percent drop in A1C.
“For just an app, this is an incredible result,”
said mySugr CEO Frank Westerman.
“It shows that especially with these populations that are at high risk, we were able to [produce] significant impact on the diabetes management.”
He continued with:
“this was a population that was only using the mySugr app. No coaching, no calculator, really the plain logging app.”
It is not however still clear if the general population will receive same effects when using this app. Participants of this study were all picked from the pool of high-engagement users that checked the app more than five times per day over the trial period of 6 months.
The results of this study were presented to the public during International Conference on Advanced Technologies and Treatments for Diabetes.
“The first couple of years we’ve been kind of a lonely voice in an empty room,”
said Frank Westerman.
“The patients pretty much embraced digital health from the start on, but it took a while until the industry got more and more involved and interested in digital health. And what we see now is the second wave, which is the payer also gets more and more interested. And they’re not only interested but ready to really make deals. In the US, we see the market is a little more mature, but in Germany, we are able to sign large volume payer deals now.”
You may be interested
Aleve Direct Therapy from Bayer can relieve your back painTelehealther - Jun 26, 2017
Bayer, a German multinational chemical, pharmaceutical and life sciences company, has announced the release of their new consumer TENS (Transcutaneous…
Medical specialties that can change the future of healthcareTelehealther - Jun 26, 2017
Many technological advancements have already managed to find their place in health clinics, and just around the corner are new…